Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Efficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's Syndrome

This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of vascular Behçet's syndrome.

Study Overview

• Status: Recruiting
• Conditions: Aneurysm; Behcet Syndrome, Vascular Type
• Intervention / Treatment: Drug: tocilizumab; Drug: tofacitinib; Drug: cyclophosphamide

Detailed Description

Behçet's Syndrome (BS) is a recurrent and systemic vasculitis, with an incidence rate of about 14/100,000 in China, higher than that in Europe and America. Vascular Behcet's Syndrome (VBS) is an important subtype of BS characterized by multiple venous and artery lesions. It affects 20-25% of BS patients, predominantly young adult males, and is the leading cause of mortality in BS patients (67%), especially in patients with aneurysms. Therefore, exploring the diagnosis and treatment strategies for VBS is key to improving the prognosis of BS.

This project aims to investigate the efficacy and safety of the combination of glucocorticoids (GCS) with the biologic agent tocilizumab or the targeted small molecule tofacitinib, compared to the combination of GCS with cyclophosphamide in the treatment of VBS aneurysms, as well as to screen for biomarkers related to the response of tocilizumab or tofacitinib, and to improve the assessment and treatment of VBS and establish a precision diagnosis and treatment strategy.

This is a Phase IIb, multi-center, randomized, open-label, GCS plus cyclophosphamide-controlled, parallel design, prospective clinical study. Patients will be randomly assigned to three groups in a 1:1:1 ratio (tocilizumab + GCS vs tofacitinib + GCS vs cyclophosphamide + GCS, 27:27:27) after screening and recruitment. Patients will be followed up every 4 weeks from weeks 0-12, and every 6 weeks from weeks 12-24. The primary endpoint is the complete remission (CR) rate at the 12th-week follow-up. All participants will undergo their final visit at 24 weeks.

• Study Type: Interventional
• Enrollment (Estimated): 81
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Jinjing Liu, M.D.; Phone Number: 8613581605769; Email: wingsforjane@163.com
• Study Contact Backup: Name: Wenjie Zheng, M.D.; Phone Number: 8613661281939; Email: wenjzheng@gmail.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Recruiting
      • Peking Union Medical College Hospital
      • Contact: Jinjing Liu
      • Principal Investigator: Wenjie Zheng, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1． Understand and voluntarily sign an informed consent form prior to any study-related assessments/procedures being conducted.

2. Male and female subjects aged 18-65 years.

3． Fulfill the 2013 International Classification Criteria for Behcet's Disease (ICBD).

4． Patients with aneurysmal dilatation/aneurysm of the descending aorta and/or peripheral arteries confirmed by ultrasonography and/or computed tomography angiography (CTA).

5. Elevated acute phase reactants ESR and hs-CRP.

Exclusion Criteria:

1. Cardiovascular manifestations that cannot be distinguished from giant cell arteritis, Burger's disease, or atherosclerotic aneurysm; infectious aneurysm;
2. Other active organ involvement related to BS that requires intensified immunosuppressive treatment, including gastrointestinal ulcers, uveitis, and parenchymal neurological involvement;
3. Patients with severe aneurysms requiring emergency intervention surgery; patients with elective surgery indications require the consensus between rheumatologists and vascular surgeons to determine inclusion or exclusion.
4. Severe organ dysfunction, including ALT, AST, and TBIL exceeding the upper limit of normal by more than 2 times, serum creatinine ≥ 133 mmol/L, white blood cell count < 3×10^9/L, ANC < 2×10^9/L, hemoglobin < 80g/L, platelet count < 100×10^9/L;
5. Active infection such as active tuberculosis, hepatitis B or C, syphilis, chronic EBV infection, persistent or severe bacterial or viral infection;
6. Primary or secondary immunodeficiency;
7. Malignant tumor;
8. Use of immunosuppressants such as Cyclosporin A (CsA), Azathioprine (AZA), Tacrolimus (TAC), Mycophenolate Mofetil (MMF), or Cyclophosphamide (CTX) within 1 month;
9. Use of biologics/small molecule drugs within 5 half-lives (baricitinib within 10 days; etanercept within 4 weeks; infliximab within 8 weeks; adalimumab, golimumab, ustekinumab, and abatacept within 10 weeks, secukinumab within 6 months, and previously use of tocilizumab and tofacitinib);
10. Pregnant, lactating, or planning a recent pregnancy;
11. Subjects who do not agree to or are unable to comply with regular visits.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tocilizumab+GCS for VBS; Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.	Drug: tocilizumab; Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.; Other Names: ACTEMRA®
Experimental: Tofacitinib+GCS for VBS; Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with oral tofacitinib 5mg twice a day for 24 weeks of treatment.	Drug: tofacitinib; Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.; Other Names: Xeljanz®
Experimental: Cyclophosphamide+GCS for VBS; Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.	Drug: cyclophosphamide; Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.; Other Names: Endoxana

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The primary endpoint is the complete response (CR) rate at week 12.	CR: the resolution of VBS-related symptoms and abnormal acute phase reactants including erythrocyte sedimentation rate (ESR) and high-sensitivity C reactive protein (hs-CRP), no progression or new occurrence of vascular lesions compared to baseline.	Baseline to week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The secondary endpoints include CR rate at week 24, and partial response (PR) rate at week 12/24.	PR: improvement in clinical symptoms, >50% decrease in inflammatory markers, no progression or new occurrence of vascular lesions.	Baseline to week 24
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF).	The BDCAF consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BS involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. The Patient's Perception of Disease Activity and the Clinician's Overall Perception of Disease Activity were assessed on a scale from 1 to 7. A higher score indicates a higher level of disease activity (worsening), and a negative change from baseline indicates improvement.	BDCAF were assessed at weeks 0, 4, 8, 12, 18, and 24
Change From Baseline in the degree of vasculitis damage as Measured by Behçet's syndrome Overall Damage Index (BODI).	The BODI consists of 4 overarching principles and 34 items with 12 subitems, categorized into 9 organ/system domains: mucocutaneous, musculoskeletal, ocular, vascular, cardiovascular, neuropsychiatric, gastrointestinal, reproductive system, and miscellaneous. Each item and subitem score 1 point. The total score ranges from 0 to 46. The higher the score, the greater the degree of damage.	BODI were assessed at weeks 0 and 24
4.Change From Baseline in the degree of vasculitis damage as Measured by Vasculitis Damage Index (VDI).	The VDI consists of 64 items, categorized into 11 organ/system domains: musculoskeletal, skin, ear, nose, and throat, pulmonary, cardiovascular, renal, gastrointestinal, peripheral vascular, ocular, neuropsychiatric, and other damage. Each item scores 1 point. The total score ranges from 0 to 64. The higher the score, the greater the degree of damage.	Time Frame: VDI were assessed at weeks 0, 12, and 24
Change From Baseline in ESR and hs-CRP.	The ESR and hs-CRP are acute phase reactants that are indicative of the patient's degree of disease activity.	ESR and hs-CRP were assessed at weeks 0, 4, 8, 12, 18, and 24
6.Change From Baseline in imaging changes including vascular ultrasonography, and CTA (including progression, improvement, and stability)	Radiological improvements is defined as the attenuation of radiological abnormalities related to VBS, including a reduction in aneurysm size. Radiological progression is defined as an increase in aneurysm size, aneurysm rupture, or the appearance of new lesions. Radiological stability is defined as the maintenance of aneurysm size and the absence of new lesions.	Imaging examinations were assessed at weeks 0, 12 and 24
7.Change From Baseline in 36 health survey questionnaire (SF-36).	The SF-36 is primarily used to evaluate eight dimensions of health-related quality of life: physical functioning (PF), role limitations due to physical health problems (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). In addition, there is a health transition (HT) item that assesses the overall change in health status over the past year. SF-36 also includes another health indicator, Reported Health Transition, which is used to evaluate the overall change in health status over the past year. Higher scores indicate better health status.	SF-36 were assessed at weeks 0, 12, and 24
Safety assessment: Record the types, frequency, and severity of adverse events, as well as the number of study participants who were discontinued due to any adverse events.	Adverse event: Any medical condition that affects the health of the participant during the study or worsens a pre-existing medical condition, regardless of whether it is causally related to the study, is considered an adverse event. This can be symptoms, signs, or abnormal laboratory tests. Serious adverse event (SAE): Any significant medical event that causes death, is life-threatening, requires hospitalization, results in permanent or severe disability or loss of function, or the investigator deems it a significant medical event that may seriously harm the participant or require medical intervention to prevent the above outcomes. The causal relationship between the serious adverse event and the study is determined by the investigator's discussion.	Adverse events were assessed at weeks 0, 4, 8, 12, 18, and 24

Collaborators and Investigators

• Sponsor: Peking Union Medical College Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: April 26, 2023
• First Submitted That Met QC Criteria: April 26, 2023
• First Posted (Actual): May 6, 2023

Study Record Updates

• Last Update Posted (Actual): August 19, 2024
• Last Update Submitted That Met QC Criteria: August 16, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: Tocilizumab; Tofacitinib; Vascular Behçet's Syndrome
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Eye Diseases; Disease; Genetic Diseases, Inborn; Stomatognathic Diseases; Mouth Diseases; Uveitis, Anterior; Panuveitis; Uveitis; Uveal Diseases; Vasculitis; Hereditary Autoinflammatory Diseases; Skin Diseases, Genetic; Skin Diseases, Vascular; Syndrome; Behcet Syndrome; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Protein Kinase Inhibitors; Janus Kinase Inhibitors; Cyclophosphamide; Tofacitinib
• Other Study ID Numbers: TCZ/TOF-VBS-PUMCH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No